Evidence map›Paper›PMID 42512421›Full record

ReviewCancers2026

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.

Timothy Pluard, Thomas Grinda, Rodrigo Dienstmann, Marc Thill, Beata Korytowsky, Connie Chen, Sofiya Portuhay, Elizabeth M Salvo-Halloran, Imtiaz A Samjoo, Nadia Harbeck

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Timothy PluardHematology and Medical Oncology, St. Luke's Cancer Institute, Kansas City, MO 64111, USA.ORCID 0000-0002-3640-3077
Thomas GrindaDepartment of Cancer Medicine, Gustave Roussy Institute, 94800 Villejuif, France.ORCID 0000-0002-8567-9627
Rodrigo DienstmannVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Marc ThillDepartment of Gynecology and Gynecologic Oncology, Agaplesion Markus Hospital, 60431 Frankfurt am Main, Germany.
Beata KorytowskyPfizer, Inc., New York, NY 10001, USA.
Connie ChenPfizer, Inc., New York, NY 10001, USA.
Sofiya PortuhayValue & Evidence, EVERSANATM, Burlington, ON L7N 3H8, Canada.
Elizabeth M Salvo-HalloranValue & Evidence, EVERSANATM, Burlington, ON L7N 3H8, Canada.
Imtiaz A SamjooValue & Evidence, EVERSANATM, Burlington, ON L7N 3H8, Canada.ORCID 0000-0003-1415-8055
Nadia HarbeckBreast Center, Department of Gynecology and Obstetrics and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital, 81377 Munich, Germany.ORCID 0000-0002-9744-7372

Funding

Pfizer (United States) Not Applicable
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

abemaciclibCDK4/6 inhibitorscomparative effectivenessmetastatic breast canceroverall survivalpalbociclibreal-world evidencereal world progression-free survivalribociclib

Identifiers

PMID42512421
PMCPMC13406782

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.